Trials / Unknown
UnknownNCT06218771
A Study of TQB3454 Tablets in Patients With Blood Tumors
A Phase Ib Clinical Trial of TQB3454 Tablets in Patients With Blood Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to evaluate the safety of TQB3454 tablets in patients with acute myeloid leukemia and myelodysplastic syndrome, and determine the phase II recommended dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3454 Tablets | TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor |
Timeline
- Start date
- 2023-07-10
- Primary completion
- 2025-06-01
- Completion
- 2025-12-01
- First posted
- 2024-01-23
- Last updated
- 2024-01-23
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06218771. Inclusion in this directory is not an endorsement.